All companies › ORKA

ORKA · Oruka Therapeutics, Inc.

Everything on this page is public record — SEC Form 4 filings and congressional disclosures — alongside any INSIDER SCANNER research case for this company.

Open-market buys0
Open-market sells5
Research cases0
Last filing2026-09-01

Insider flow: Selling only — a count of disclosed transactions, not a rating or a recommendation.

Insider transaction timeline

Every reported transaction, positioned by trade date. Purchases sit above the axis, sales below; circle area is proportional to dollar value. No share-price line is drawn — this feed carries transaction prices only, and a price history inferred from them would imply market data the filings do not contain.

Open-market purchase Open-market sale
2026-09-01 — Sandler Laura Lee · sold 1,000 @ $91.05 2026-09-01 — Sandler Laura Lee · sold 4,000 @ $92.01 2026-09-01 — Klein Lawrence Otto · sold 6,604 @ $90.79 2026-09-01 — Klein Lawrence Otto · sold 63,596 @ $91.90 2026-09-01 — Klein Lawrence Otto · sold 4,800 @ $92.44
2026-09-012026-09-01

Insider participation

One row per insider, one cell per reported transaction, shaded by value. Repeat buying and activity clustered in time are visible at a glance.

Klein Lawrence Otto Chief Executive Officer
Sandler Laura Lee Chief Operating Officer
Included with a free account

The analysis built on top of these filings

The filings above are public record and stay public here. What an account adds for $ORKA is the reading of them — and for this company, that is what the list below says it is, no more.

  • Transaction timelineThe [{'transaction_date': '2026-09-01', 'insider_name': 'Sandler Laura Lee', 'insider_title': 'Chief Operating Officer', 'transaction_type': 'Open-market sell', 'shares': 1000.0, 'price': 91.0476, 'value': 91047.6, 'is_buy': False}, {'transaction_date': '2026-09-01', 'insider_name': 'Sandler Laura Lee', 'insider_title': 'Chief Operating Officer', 'transaction_type': 'Open-market sell', 'shares': 4000.0, 'price': 92.0134, 'value': 368053.6, 'is_buy': False}, {'transaction_date': '2026-09-01', 'insider_name': 'Klein Lawrence Otto', 'insider_title': 'Chief Executive Officer', 'transaction_type': 'Open-market sell', 'shares': 6604.0, 'price': 90.7868, 'value': 599556.03, 'is_buy': False}, {'transaction_date': '2026-09-01', 'insider_name': 'Klein Lawrence Otto', 'insider_title': 'Chief Executive Officer', 'transaction_type': 'Open-market sell', 'shares': 63596.0, 'price': 91.8963, 'value': 5844237.09, 'is_buy': False}, {'transaction_date': '2026-09-01', 'insider_name': 'Klein Lawrence Otto', 'insider_title': 'Chief Executive Officer', 'transaction_type': 'Open-market sell', 'shares': 4800.0, 'price': 92.4357, 'value': 443691.36, 'is_buy': False}] reported transactions plotted over the window rather than listed, so concentration is visible.

Not available for ORKA today: no reported open-market purchases in this window, so there is no insider cost basis to compute; no research case — nothing here has cleared the scoring threshold. Both appear on this page on their own if that changes.

A free account opens all of it.

Not financial advice. This page reports public filings and past research output. It is not a recommendation to buy or sell, and no price target here is a prediction. Trade at your own risk.